Benzoxazepine-Derived Selective, Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase
作者:Gleb Andryianau、Michal Kowalski、Michal C. Piotrowicz、Adam A. Rajkiewicz、Barbara Dymek、Piotr L. Sklepkiewicz、Elzbieta Pluta、Filip Stefaniak、Wojciech Czestkowski、Sylwia Olejniczak、Marzena Mazur、Piotr Niedziejko、Robert Koralewski、Krzysztof Matyszewski、Mariusz Gruza、Agnieszka Zagozdzon、Magdalena Salamon、Aleksandra Rymaszewska、Mikolaj Welzer、Karolina Dzwonek、Jakub Golab、Jacek Olczak、Agnieszka Bartoszewicz、Adam Golebiowski
DOI:10.1021/acsmedchemlett.0c00092
日期:2020.6.11
Human acidic mammalian chitinase (hAMCase) is one of two true chitinases in humans, the function of which remains elusive. In addition to the defense against highly antigenic chitin and chitin-containing pathogens in the gastric and intestinal contents, AMCase has been implicated in asthma, allergic inflammation, and ocular pathologies. Potent and selective small-molecule inhibitors of this enzyme
人类酸性哺乳动物几丁质酶(hAMCase)是人类中两种真正的几丁质酶之一,其功能仍然难以捉摸。除了防御胃和肠内容物中的高度抗原性甲壳质和含甲壳质的病原体外,AMCase还涉及哮喘,过敏性炎症和眼部疾病。迄今为止,尚未发现该酶的强效和选择性小分子抑制剂。在这里,我们描述了化合物OAT-177的结构修饰,该化合物是先前开发的小鼠AMCase抑制剂,导致OAT-1441表现出高活性和对hAMCase的选择性。OAT-1441大大降低了对人类以太相关基因(hERG)的脱靶活性,并具有良好的药代动力学特征 是进一步临床前开发的潜在候选药物,也是研究hAMCase生理作用的有用工具化合物。